[go: up one dir, main page]

PE20130308A1 - Metodos para tratar infecciones bacterianas recurrentes - Google Patents

Metodos para tratar infecciones bacterianas recurrentes

Info

Publication number
PE20130308A1
PE20130308A1 PE2012002184A PE2012002184A PE20130308A1 PE 20130308 A1 PE20130308 A1 PE 20130308A1 PE 2012002184 A PE2012002184 A PE 2012002184A PE 2012002184 A PE2012002184 A PE 2012002184A PE 20130308 A1 PE20130308 A1 PE 20130308A1
Authority
PE
Peru
Prior art keywords
methods
composition
bacterial infections
treat
subject
Prior art date
Application number
PE2012002184A
Other languages
English (en)
Inventor
Youe-Kong Shue
Sherwood Gorbach
Pamela Sears
Original Assignee
Optimer Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44992320&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20130308(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Optimer Pharmaceuticals Inc filed Critical Optimer Pharmaceuticals Inc
Publication of PE20130308A1 publication Critical patent/PE20130308A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UN METODO PARA TRATAR UNA INFECCION GASTROINTESTINAL RECURRENTE DE CLOSTRIDIUM DIFFICILE EN UN SUJETO QUE HA SIDO SOMETIDO A MAS DE UN TRATAMIENTO PREVIO, DICHO METODO COMPRENDE ADMINISTRAR A UN SUJETO UNA COMPOSICION FARMACEUTICA QUE CONTIENE UN COMPUESTO DE FORMULA (I) E HIDROXITOLUENO BUTILADO. LA COMPOSICION FARMACEUTICA COMPRENDE AL MENOS 93% DEL COMPUESTO DE FORMULA (I), LA CUAL SE ADMINISTRA EN FORMA DE UNA TABLETA, CAPSULA O SUSPENSION
PE2012002184A 2010-05-18 2011-05-18 Metodos para tratar infecciones bacterianas recurrentes PE20130308A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34592310P 2010-05-18 2010-05-18

Publications (1)

Publication Number Publication Date
PE20130308A1 true PE20130308A1 (es) 2013-04-06

Family

ID=44992320

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012002184A PE20130308A1 (es) 2010-05-18 2011-05-18 Metodos para tratar infecciones bacterianas recurrentes

Country Status (9)

Country Link
US (1) US20140315838A1 (es)
AU (1) AU2011255633B2 (es)
BR (1) BR112012029262A8 (es)
CA (1) CA2799531A1 (es)
CL (1) CL2012003202A1 (es)
CO (1) CO6670519A2 (es)
MX (1) MX2012013372A (es)
PE (1) PE20130308A1 (es)
WO (1) WO2011146624A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6134739B2 (ja) * 2012-01-23 2017-05-24 サンタリス ファーマシューティカルズ インコーポレイテッド ビャクダン油およびクロストリジウム感染症に関連するその使用
WO2013138748A1 (en) * 2012-03-16 2013-09-19 Optimer Pharmaceuticals, Inc. Prevention of clostridium difficile infection in high risk patients
US20150141356A1 (en) * 2013-11-15 2015-05-21 Optimer Pharmaceuticals, Inc. Treatment of Clostridium Difficile Infection in High Risk Patients
CN110037992B (zh) * 2019-05-28 2021-05-28 杭州华东医药集团新药研究院有限公司 一种稳定的非达霉素组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7906489B2 (en) * 2004-05-14 2011-03-15 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
US7378508B2 (en) * 2007-01-22 2008-05-27 Optimer Pharmaceuticals, Inc. Polymorphic crystalline forms of tiacumicin B
US20080176927A1 (en) * 2007-01-19 2008-07-24 Optimer Pharmaceuticals, Inc. Compositions of stable tiacumicins

Also Published As

Publication number Publication date
AU2011255633B2 (en) 2014-09-11
CO6670519A2 (es) 2013-05-15
WO2011146624A9 (en) 2012-05-10
CL2012003202A1 (es) 2013-07-12
BR112012029262A2 (pt) 2017-07-11
BR112012029262A8 (pt) 2018-06-12
CA2799531A1 (en) 2011-11-24
AU2011255633A1 (en) 2013-01-10
MX2012013372A (es) 2013-05-01
WO2011146624A2 (en) 2011-11-24
US20140315838A1 (en) 2014-10-23

Similar Documents

Publication Publication Date Title
EA201491358A1 (ru) Вводимые перорально кортикостероидные композиции
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
EA033067B1 (ru) Способ лечения метаболических расстройств у пациента, имеющего противопоказание к назначению бигуанидного соединения
UA109991C2 (xx) Карбаматні сполуки, їх отримання і застосування
NZ629996A (en) 2’- substituted carba-nucleoside analogs for antiviral treatment
CO6592104A2 (es) Compuesto heterociclico
EA201490228A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
EA201690069A1 (ru) Применение высоких доз придопидина для лечения болезни хантингтона
PH12015500407B1 (en) Methods of treating hypertriglyceridemia
HK1218560A1 (zh) 组成与方法
EA201491060A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
CR11724A (es) Agente para tratar enfermedades
EA201390626A1 (ru) Производные гидроксамовой кислоты и применение указанных производных в лечении бактериальных инфекций
MX340985B (es) Compuestos de n-heteroarilo.
PH12014500386A1 (en) Combination treatment for hepatitis c
MX2017003780A (es) Composicion farmaceutica para tratar colitis ulcerativa.
AR091351A1 (es) Formulaciones de bromocriptina, metodo para mejorar el control glucemico y metodo para la fabricacion
CL2011001943A1 (es) Terapia antibiotica para tartar o prevenir el sindrome del intestino irritable post- infeccioso.
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
MX2012013879A (es) Derivados de hidroxipiridona, composiciones farmceuticas de los mismos y su uso terapeutico para tratar enfermedades proliferativas.
MX2020007462A (es) Metodos de tratamiento de enfermedades inflamatorias cronicas.
BR112014008783A2 (pt) compostos para o tratamento e profilaxia da doença causada por vírus sincicial respiratório
MX2016000294A (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
PE20130308A1 (es) Metodos para tratar infecciones bacterianas recurrentes
BR112012006070A2 (pt) composições e métodos para tratar distúrbios convulsivos.

Legal Events

Date Code Title Description
FC Refusal